Advancing genomics, medicine and health together – by semiconductor DNA synthesis technology

In this webinar, Dr. Josh Wang, Scientist and Leader in the Research and Development group at GenScript, provides an overview of new Next Generation Sequencing (NGS) reagents.

Before discussing NGS solutions, Dr. Wang highlighted GenScript’s efforts during the current COVID pandemic to develop services and products in support of SARS-CoV-2 research, diagnostics and vaccine development worldwide.

NGS and Personalized Precision Medicine

A broad range of research fields continue to benefit from NGS approaches. More importantly, NGS has the potential to shape diagnostics and therapeutic approaches by providing precise gene sequencing information. Precision medicine aims at leveraging NGS derived information about an individual’s disease underscoring mutations to guide personalized medical treatments.

Basics of NGS Workflow

Different platforms support massively parallel sequencing, which vary in throughput but operate based on the same underlying chemistry of sequencing by synthesis. Briefly, the workflow starts with NGS library preparation, where specific DNA sequences or adapters are ligated to genomic DNA fragments. Next, the generated library is loaded onto a flow cell for bridge amplification, where the library is copied onto the flow cell, a process commonly referred to as clustering. DNA fragments amplified onto the flow cell are sequenced through Sanger like sequencing reactions, where millions of clusters are sequenced in a massively parallel process. Lastly, millions of reads are analyzed for nucleotide identification or base calling assessment and alignment to reference sequences.

GenScript’s NGS Solutions

GenScript has developed multiple reagents to simplify the NGS workflow and optimize NGS targeted applications.

Do you like the current new website?